title: [The use of endolymphatic chemotherapy in patients with metastatic stomach cancer].
abstract: The results of the endolymphatic chemotherapy application in patients with metastatic cancer of stomach are presented. The low toxicity and high effectiveness were suggested. One-year survival was achieved in 42.2% of patients.
authors: G V
authors: GV
authors: Bondar'
authors: A F
authors: AF
authors: Zabudkin
authors: S V
authors: SV
authors: Bukhteev
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007272:Injections, Intralymphatic; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate
vernacular_title: Primenenie éndolimfaticheskoĭ khimioterapii u bol'nykh s metastaticheskim rakom zheludka.